New #Stocks to Watch at Investor Ideas: (Nasdaq: $BFRI)
(Nasdaq: $CGTX) (Nasdaq: $EXAI) (CSE: $PBF.C) (CSE: $STGX.C) (CSE: $MJEM.C)
#Biotech, #Mining, #Plant-Based and #Tech Stocks to
Watch
Point Roberts WA, Delta BC, January 14, 2022 –
(Investorideas.com Newswire) Investorideas.com, a global news source and
expert investing resource, announces its weekly roundup of stocks to watch in
Biotech, Mining, Plant-Based and Tech. Today’s
stocks have been added to our lists of free stock directories in each sector.
Read this in full at https://www.investorideas.com/news/2022/main/01141Stocks.asp
The newest biotech companies are involved in
treatments of dermatological conditions, CNS and cancer
among other diseases.
The latest mining company is focused on cobalt
and ‘green metals’, while the newest plant-based company offers a vegan meat alternative derived from hemp.
The newest tech company is a social media company for Generation Z’s.
New stocks added to the Biotech Stock Directory:
Biofrontera Inc. (Nasdaq: BFRI) is a U.S.-based
biopharmaceutical company commercializing a portfolio of pharmaceutical
products for the treatment of dermatological conditions with a focus on
photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed
products are used for the treatment of actinic keratoses, which are
pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.
COGNITION THERAPEUTICS INC (Nasdaq: CGTX) is a clinical-stage
biopharmaceutical company engaged in the discovery and development of
innovative, small molecule therapeutics targeting age-related degenerative
diseases and disorders of the central nervous system, or CNS, and retina. Our
goal is to develop disease modifying treatments for patients with these
degenerative disorders by initially leveraging our expertise in the σ-2
(sigma-2) receptor, or S2R, which is expressed by multiple cell types,
including neuronal synapses, and acts as a key regulator of cellular damage
commonly associated with certain age-related degenerative diseases of the CNS
and retina. We believe that targeting the S2R complex represents a mechanism
that is functionally distinct from other current approaches in clinical
development for the treatment of degenerative diseases.
Exscientia Ltd. (Nasdaq: EXAI) is an AI-driven
pharmatech company committed to discovering, designing and developing the best
possible drugs in the fastest and most effective manner. Exscientia developed
the first-ever functional precision oncology platform to successfully guide
treatment selection and improve patient outcomes in a prospective
interventional clinical study, as well as to progress AI-designed small
molecules into the clinical setting. Our pipeline of internal and partnered
programmes demonstrates our ability to rapidly translate scientific concepts
into precision-designed therapeutic candidates, with more than 25 projects
advancing, including the first three AI-designed drug candidates to enter Phase
1 clinical trials. Exscientia has offices in Oxford, Vienna, Dundee, Miami,
Boston, and Osaka
IO Biotech, Inc. (Nasdaq: IOBT) is
a clinical-stage biopharmaceutical company developing novel, immune-modulating
cancer therapies based on its T-win® technology platform. The T-win® platform
is a novel approach to cancer immunotherapy designed to activate naturally
occurring T cells to target immunosuppressive mechanisms. IO Biotech is
advancing its lead immuno-oncology candidate, IO102-IO103, targeting IDO and
PD-L1, in clinical studies and its other pipeline candidates through clinical
and preclinical development. IO Biotech is headquartered in Copenhagen,
Denmark, and has additional offices within the United States (New York, New
York and Rockville, Maryland) and United Kingdom (Monmouthshire).
LianBio (NasdaqGM:LIAN) is
a cross-border biotechnology company on a mission to bring transformative
medicines to historically underserved patients in China and other Asian
markets. Through partnerships with highly innovative biopharmaceutical
companies around the world, LianBio is advancing a diversified portfolio of
clinically validated product candidates with the potential to drive new
standards of care across cardiovascular, oncology, ophthalmology, inflammatory
disease and respiratory indications. LianBio is establishing an international
infrastructure to position the company as a partner of choice with a platform
to provide access to China and other Asian markets.
MiNK Therapeutics, Inc. (Nasdaq: INKT) is a clinical-stage biopharmaceutical company
pioneering the discovery, development, and commercialization of allogeneic
invariant natural killer T (iNKT) cell therapies to treat cancer and other
immune-mediated diseases. MiNK is advancing a pipeline of both native and
next-generation engineered iNKT programs, with a platform designed to
facilitate scalable and reproducible manufacturing for off-the-shelf delivery.
Pyxis Oncology, Inc. (Nasdaq PYXS) is a preclinical oncology company focused on
developing an arsenal of next-generation therapeutics to target
difficult-to-treat cancers and improve quality of life for patients. Pyxis
develops its product candidates with the objective to directly kill tumor
cells, and to address the underlying pathologies created by cancer that enable
its uncontrollable proliferation and immune evasion. Since its launch in 2019,
Pyxis has developed a broad portfolio of novel antibody drug conjugate, or ADC,
product candidates, and monoclonal antibody, or mAb, preclinical discovery
programs that it is developing as monotherapies and in combination with other
therapies.
Theseus Pharmaceuticals, Inc. (Nasdaq:THRX) is a biopharmaceutical company focused on
improving the lives of cancer patients through the discovery, development and
commercialization of transformative targeted therapies. Theseus is developing
next-generation tyrosine kinase inhibitors (TKIs): "pan-variant"
targeted therapies that address all major drug resistance mutations. Theseus'
lead product candidate, THE-630, is a pan-variant KIT inhibitor for the
treatment of patients with advanced gastrointestinal stromal tumors (GIST),
whose cancer has developed resistance to earlier lines of kinase inhibitor
therapy. Theseus is also developing a fourth-generation, selective epidermal
growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first-
or later-line osimertinib treatment in patients with non-small cell lung cancer
(NSCLC).
Vaxxinity,
Inc. (NasdaqGM:VAXX) is
purpose-driven biotechnology company committed to democratizing healthcare
across the globe. The company is pioneering a new class of synthetic,
peptide-based immunotherapeutic vaccines aimed at disrupting the existing treatment
paradigm for chronic disease, increasingly dominated by monoclonal antibodies,
which suffer from prohibitive costs and cumbersome administration. The
company’s proprietary technology platform has enabled the innovation of novel
pipeline candidates designed to bring the efficiency of vaccines to the
treatment of chronic diseases, including Alzheimer’s, Parkinson’s, migraine,
and hypercholesterolemia. The technology is also implemented as part of a
COVID-19 vaccine program. Vaxxinity has optimized its pipeline to achieve a
potentially historic, global impact on human health.
New stocks added to the Mining Stocks Directory:
StrategX Elements
Corp.
(CSE:STGX) is an exploration
company poised to be a significant contributor in the green energy sector and
emerging low carbon economy. The Company is currently focused on discovery of
cobalt and associated ‘green’ metals in northern Canada. The Company’s property
portfolio includes two new regional plays: Project 939 & EA South situated
near the shores of the East Arm of the Great Slave Lake, Northwest Territories,
and Project M on the Melville peninsula, Nunavut, also located close to
tidewater.
New stocks added to the Plant-Based Stocks Directory:
Planet Based Foods Global Inc. (CSE:PBF) is focused
on producing natural, low processed and nutritional choices that are better for
people and the planet. The Company currently offers a high quality,
cost-efficient vegan meat alternative derived from hemp proteins including
burgers, breakfast sausages, burger crumbles and sausage crumbles.
New stocks added to the Tech Stocks Directory:
Mijem Newcomm Tech Inc. (CSE:MJEM) is a
social media and technology company providing innovative solutions to create a
vibrant social marketplace for Generation Z communities, such as students, to
connect and to efficiently buy, sell and trade goods and services on and off
campus.
The directories are not meant as recommendations
but as a research tool to discover opportunities and trading ideas in a
particular sector.
Investors can trade these stocks and other ideas on our site using our list of top stock trading apps including Robinhood, Acorn, Stash and others.
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com publishes breaking stock news,
third party stock research, guest posts and original articles and podcasts in
leading stock sectors. Learn about
investing in stocks and get investor ideas in cannabis, crypto, AI and IoT,
mining, sports biotech, water, renewable energy, gaming and more. Investor Idea’s
original branded content includes podcasts and columns : Crypto
Corner , Play by Play sports and
stock news , Investor Ideas Potcasts Cannabis News and Stocks on the Move
podcast , Cleantech and Climate Change , Exploring Mining , Betting on Gaming Stocks Podcast and the AI Eye
Podcast.
Learn about investing in
stocks and sector trends with our news alerts, articles, podcasts and videos, looking
at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable
energy and more. Investor Idea's original branded content includes the
following podcasts and columns: Crypto
Corner, Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column, Cleantech and Climate Change, Exploring Mining and the AI Eye.
Public companies within the
sectors we cover use our news and content services to
tell their story to interested investors. Paid for content is
disclosed.
Disclaimer/Disclosure: Investorideas.com is a digital publisher of
third party sourced news, articles and equity research as well as creates
original content, including video, interviews and articles. Original content
created by investorideas is protected by copyright laws other than syndication
rights. Our site does not make recommendations for purchases or sale of stocks,
services or products. Nothing on our sites should be construed as an offer or
solicitation to buy or sell products or securities. All investing involves risk
and possible losses. This site is currently compensated for news publication
and distribution, social media and marketing, content creation and more.
Disclosure is posted for each compensated news release, content published
/created if required but otherwise the news was not compensated for and was
published for the sole interest of our readers and followers. Contact
management and IR of each company directly regarding specific questions. More
disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news
services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, PR and social media,
podcast and ticker tag services at Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Learn more about advertising and guest posts
https://www.investorideas.com/Advertise/
Follow us on Twitter https://twitter.com/Investorideas
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Download our Mobile App for iPhone and Android
Join our Investor Club
https://www.investorideas.com/membership/
Contact
Investorideas.com
800 665 0411
No comments:
Post a Comment